

§Appl. No. 09/996,956  
Amdt. dated February 13 2004  
Reply to Office Action of, October 14, 2003

**Listing of Claims:**

Please **amend** the claims as follows:

**Claim 1** (Currently Amended) An isolated polynucleotide which is selectively expressed in prostate, comprising: the nucleotide sequence of PR33a ~~from nucleotide positions 1-5198 as set forth in SEQ ID NO. 1, the nucleotide sequence of PR33a from nucleotide positions 1763-5198,~~ or complements 100% identical thereto.

**Claim 2.** (Currently Amended) An isolated polynucleotide comprising of claim 1, which ~~comprises~~ the nucleotide sequence of PR33a from nucleotide positions 1-5198 as set forth in SEQ ID NO. 1.

**Claim 3** (Currently Amended) An isolated polynucleotide comprising of claim 1, which ~~comprises~~ the nucleotide sequence of PR33a from nucleotide positions 1763-5198 as set forth in SEQ ID NO. 1.

**Claim 4.** (Canceled)

**Claim 5** (Original) An isolated polynucleotide probe for prostate, comprising:  
SEQ ID NOS 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or a complement thereto.

**Claim 6** (Original) An isolated probe of claim 5, which consists essentially of SEQ ID NOS 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or a complement thereto.

§Appl. No. 09/996,956  
Amdt. dated February 13 2004  
Reply to Office Action of, October 14, 2003

**Claim 7 (Original)** A method of detecting prostate tissue in a sample comprising nucleic acid, comprising:

contacting said sample with a polynucleotide probe under conditions effective for said probe to hybridize specifically to a nucleic acid of claim 1 in said sample, and

detecting the presence or absence of probe hybridized to said nucleic acid in said sample, wherein said probe is a polynucleotide which is PR33a as set forth in SEQ ID NO. 1, PR33b as set forth in SEQ ID NO. 3, PRB008 as set forth in SEQ ID NO. 4, complements thereto, a polynucleotide having at least 95% sequence identity thereto, or effective specific fragments thereof.

**Claim 8 (Original)** A method of claim 7, wherein said probe is a contiguous sequence of at least 8 nucleotides selected from the sequence set forth in SEQ ID NOS. 1, 3, 4, or complements thereto.

**Claim 9 (Original)** A method of claim 7, wherein said probe is selected from SEQ ID NOS. 7-16, or a complement thereto.

**Claim 10 (Original)** A method of claim 7, wherein said detecting is performed by Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, or in situ hybridization.

**Claim 11 (Original)** A method of claim 7, wherein said sample is blood, normal prostate, or prostate cancer.

§Appl. No. 09/996,956  
Amdt. dated February 13 2004  
Reply to Office Action of, October 14, 2003

**Claim 12 (Original)** A method of retrieving prostate-specific gene sequences from a computer-readable medium, comprising:

selecting a gene expression profile that specifies that said gene is selectively expressed in prostate, and

retrieving prostate-specific gene sequences, where the gene sequences comprise the sequences of claim 1.

**Claim 13 (Original)** A method of claim 12, wherein said gene has the nucleotide sequence set forth in SEQ ID NOS. 1, 3, 4, or complements thereto.

**Claim 14 (Canceled)**

**Claim 15 (Original)** A method of claim 14, wherein said detecting is performed using a gel band-shift assay.

**Claim 16 (Original)** A computer-readable storage medium, consisting essentially of, polynucleotide sequences of claim 1.

**Claim 17 (Original)** A storage medium of claim 16, wherein said gene has a nucleotide sequence set forth in SEQ ID NO. 1, 3, or 4.

**Claim 18 (Previously amended)** An array of polynucleotide probes, comprising:  
nucleic acid probes selective for PR33a or PR33b,  
wherein said probes are selected from the nucleotide sequence of PR33a from nucleotide positions 1763-5198 as set forth in SEQ ID NO. 1, the nucleotide sequence of PR33b from nucleotide positions 1655-5073 as set forth in SEQ ID NO. 3, or complements thereto, and

§Appl. No. 09/996,956  
Amdt. dated February 13 2004  
Reply to Office Action of, October 14, 2003

said probe is a contiguous sequence of at least 8 nucleotides.

**Claim 19 (Canceled)**

**Claim 20 (Canceled)**

**Claim 21 (Previously Presented)** An isolated polynucleotide which is selectively expressed in prostate, comprising: the nucleotide sequence of PR33b from nucleotide positions 1-5073 as set forth in SEQ ID NO. 3, the nucleotide sequence of PR33b from nucleotide positions 1655-5073 as set forth in SEQ ID NO 3, or complements thereto.

**Claim 22 (Previously Presented)** An isolated polynucleotide of claim 21, comprising the nucleotide sequence of PR33b from nucleotide positions 1-5073 as set forth in SEQ ID NO. 3, or a complement thereto.

**Claim 23 (Previously Presented)** An isolated polynucleotide of claim 21, comprising the nucleotide sequence of PR33b from nucleotide positions 1655-5073 as set forth in SEQ ID NO 3, or a complement thereto.